Home › News › Clinical Trials › Archive

Clinical Trial News Archive

Get news By email or subscribe to our News feeds.

All News Consumer Pharma New Drugs Pipeline Clinical Trials

July 2007

July 2

ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29 Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF) Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH) ENDEAVOR IV Clinical Trial Meets Primary Endpoint Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

July 3

Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials Researchers Discover Method for Identifying How Cancer Evades the Immune System Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference Tercica to Present at Investment Conferences

July 5

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea Avexa's Apricitabine Clinical Trial Update Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis Genzyme Announces Results of Clinical Trial of Hylastan Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference Stanford Researchers Find Brain Pathway of Depression in Rats NIEHS Researchers Identify Enzyme Critical in DNA Replication Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

July 6

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

July 9

Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference Aptuit Introduces Aptuit IVRS powered by Clarix, a Fully Web-Integrated Interactive Voice Response System Providing Customers with Easy Access to Real-Time Data Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

July 10

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis Protox Announces Positive Clinical Data from Prostate Cancer Study AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

July 11

Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent New Information on the Potential of Plasmin Shared at ISTH Congress Antibiotics Don't Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections Positive Aggrastat Results Featured in the Journal of the American College of Cardiology Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis Sygnis Pharma AG announces date for presentation of clinical results Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology

July 12

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer LAB International Announces Positive Results from its Growth Hormone Releasing Hormone (GHRH) Phase II Trial ISI Announces Regional eCTD Readiness Workshops for Electronic Submissions Progenics Selected to Present Clinical Results for Novel HIV Therapy PRO 140 at International Aids Conference CardioVascular BioTherapeutics Completes Pre-clinical Stroke Research Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial Stem Cell Clinic Publishes First Peer Reviewed Paper on Autism Stem Cell Therapy Carrington Subsidiary DelSite Demonstrates Usefulness of GelSite Polymer for Therapeutic Delivery of Proteins and Peptides at Controlled Release Society Meeting City of Hope Selects TrialMaster to support clinical trials Octagon Research Solutions Limited is Granted SME Status in EU Acusphere Presents at Controlled Release Society Celsion Reports Early Success with Second Drug Bayer HealthCare Reports Positive Preclinical Study Results on Longer-Acting Recombinant Factor VIII Molecules Karo Bio Half Year Report January - June 2007

July 16

Hollis-Eden Pharmaceuticals Reports Initial Results in Phase I Clinical Trial of HE3286 as New Type II Diabetes Treatment CardioVascular BioTherapeutics to Provide Clinical Trial Details on July 19 Conference Call Arpida Reports Positive Results of Second Pivotal Phase Iii Trial with Intravenous Iclaprim in CSSSI Drug Delivery Company Acrux Announces the Results of Its Phase 2 Male Testosterone Replacement Lotion Trial Pharsight Releases Drug Model Explorer Version 1.6 Can-Fite Reports Results of a Phase IIb Clinical Study in Rheumatoid Arthritis with CF101, an A3 Adenosine Receptor Agonist. The Results Support Further Clinical Development of CF101 BioLineRx Announces Results of Clinical Receptor-Occupancy Study of BL-1020, a First in Class GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia IBM Signs $1.4 Billion Global Strategic Outsourcing Agreement With AstraZeneca Vernalis Reports Positive Outcome of a Phase IIA Trial of V3381 In Diabetic Neuropathic Pain Study Finds COPD Patients Taking Inhaled Steroids are at Greater Risk for Severe Pneumonia Long-Sought Adaptive Trial Predictability Announced: Cytel Inc., Tourtellotte Solutions Reveal Integrated Simulators Data Supports Potential Mechanism for Gentium's Defibrotide in Cancer, Diabetic Nephropathy and Veno-Occlusive Disease Amira Pharmaceuticals Announces Positive Initial Data From a Phase 1 Study of AM103, A Novel Product Candidate for the Treatment of Respiratory and Cardiovascular Disease New Clinical Results Increase Market Potential of Cytotect

July 17

Elixir Pharmaceuticals Announces Presentation of Data in Programs to Treat and Prevent Metabolic Diseases Idera Pharmaceuticals Presents Preclinical Data of Toll-Like Receptor Antagonists in Rheumatoid Arthritis Models Metabasis Therapeutics Announces CS-917 Phase 2b Clinical Trial Results and Reports on Status of Pradefovir CVBT Announces Positive Pre-Clinical Results for Protein-Based Drug Candidate to Treat Osteoporosis Secondary Endpoints of Phase II/III Study Confirm Clear Benefits from Treatment With removab(R) for Patients with Malignant Ascites AVI BioPharma Announces Positive Pre-Clinical Study Results Presented at the 26th Annual Meeting of the American Society for Virology Idera Pharmaceuticals Announces Publication of Study of Toll-Like Receptor 9 Agonist in Combination with Avastin(R) in Preclinical Colon Cancer Model Nymox Announces New Drug Data to Be Presented at Upcoming U.S. Urology Meeting Nextrials Selected by AlwaysOn as an AO 100 Top Private Company Award Winner Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007

July 20

Journal of Clinical Oncology Publishes Data on Zolinza (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma Wyeth and Progenics Announce Positive Preliminary Results of Phase 1 Study of New Oral Formulation of Methylnaltrexone Sorel Forge Selects Amadeus eQCM Software Solution GlycoMimetics, Inc. Highlights Advances in Lead Drug Candidate for Sickle Cell Patients at International Glycobiology Conference Samaritan Announces Positive Preliminary Results in a Phase IIb Study For Its Novel Oral HIV Entry Inhibitor Improvement Following ADHD Treatment Sustained in Most Children, But Linked Problems Persist Into Adolescence -- Major Follow-up Study New Data Show Tekturna and Diovan Used Together Provide Additive Blood Pressure Reductions Pharsight Releases Drug Model Explorer Version 1.6

July 23

Advanced Magnetics Announces Positive Results from Fourth Phase III Study of Ferumoxytol as an Intravenous Iron Replacement Therapeutic in Chronic Kidney Disease Patients ANX-201 Combination Therapy Demonstrates Synergistic Inhibition of HIV-1 in Preclinical Tests Nventa Announces Publication of Final Results of a Phase 2 Study of HspE7 in Cervical Dysplasia Xencor Data Published in Journal of Immunology Demonstrate Selectivity of New Class of Inhibitors for Inflammatory Disease Pluristem's PLX Cells Show Promise in Treating Limb Ischemia Paper in Cancer Biology & Therapy Confirms In Vitro Cytotoxic Effect of Alfacell's Onconase New Interim Results Demonstrate High Response Rate With Fuzeon Plus Darunavir Regardless of Existing Protease Inhibitor Resistance 144-Week Data from Gilead's Study 934 Comparing Truvada to Combivir Both in Combination with Sustiva Presented At International AIDS Society Meeting in Sydney MedImmune Announces Interim Phase 1 Study Results for Potential Asthma Therapy Sygnis Announces Successful Completion of the Clinical IIa Study for AX200 in Stroke New Data Suggest Boosted Invirase Has Similar Efficacy to Boosted Lopinavir in HIV Patients at 24 Weeks Baxter Announces Preliminary Phase I/II Data for Seasonal Influenza Vaccine Candidate SYGNIS successfully completes clinical study IIa for AX200 in stroke (AXIS)

July 24

Isentress (raltegravir), an Investigational Oral HIV Integrase Inhibitor, in Combination Therapy Demonstrated HIV RNA Reduction Comparable to Efavirenz in Treatment-Naive HIV-Positive Patients Etrials EDC to Interface with Green Mountain Logic Labpas CT Phase IIa Study Results Demonstrate that Once-Daily 200 mg Dosing of INCB9471 Provided Potent and Prolonged Antiviral Activity in HIV-Infected Patients Vicriviroc Demonstrates Potent Viral Suppression Through 48 Weeks of Therapy in ACTG Phase II Study in Treatment-Experienced HIV Patients Starpharma Presents Positive Results of Clinical Study of VivaGel in Men at 4th International AIDS Society Conference Orexigen Therapeutics Reports Top-line 24 Week Results for Phase IIb Trial of Empatic to Treat Obesity Protalex Announces Preliminary Results in Phase I Clinical Trial Phase Forward and Sentrx Partner to Offer Integrated Drug Safety Services OrexigenReports Top-line 24 Week Results for Ph IIb EMPATIC? Obesity Trial Faster-Acting Antidepressants Closer to Becoming a Reality

July 25

New Head-to-Head Study Comparing Lexiva and Atazanavir Show Similar Efficacy and Lipid Changes Analysis of Ushercell HIV Trials Reveals Difference in Seroconversion Groups Not Statistically Significant BioSante Pharmaceuticals Announces Positive Resultsfor its CaP Technology for Use in Aesthetic Medicine BioSante Pharmaceuticals Announces Positive Results for its CaP Technology for Use in Aesthetic Medicine Targacept Presents Data from Tridmac Trial Showing Positive Effects of Mecamylamine as Augmentation Treatment for Depressed Patients Actemra monotherapy demonstrates significant clinical benefit in patients with rheumatoid arthritis Animal Studies Show Promising Therapeutic Dosing Results Using an Antisense Agent to Treat Heart Disease Panacos Announces Five Presentations on its Antiviral Programs at International AIDS Society Conference AVI BioPharma Partner Global Therapeutics Announces Positive Pre-Clinical Results Shown Using Neugene Antisense Drug in Prevention of Cardiovascular Restenosis The Journal of Hand Surgery Publishes Initial Phase III Data on Xiaflextm (formerly known as AA4500), Auxilium's Investigational Treatment for Patients with Dupuytren's Contracture Fourth Actemra (tocilizumab) Phase III Study Demonstrates Significant Clinical Benefit in RA Patients Progenics Presents Additional Positive Clinical Results for HIV-Entry Inhibitor PRO 140 at International AIDS Meeting Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show Treating HIV-Infected Infants Early Helps Them Live Longer CytoDyn Study of Bird Flu Vaccines Illustrates Subsidiary's Unique Opportunity Delphian Pharma Announces-Discovery of Novel Anti-tumor Antimitotic Agents That Also Reverse Tumor Resistance

July 31

Infringement Claims Against DATATRAK Dismissed Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Eye Disorders OncoGenex and Isis Report Encouraging Interim Phase II Data in Advanced Prostate Cancer, Affirm Phase III Clinical Trial Plans New Study Finds Tindamax to be Effective, Well-Tolerated Treatment for Bacterial Vaginosis Phase Forward Signs Multi-Year Enterprise Agreement with ICON Preliminary Data Add New Mechanistic Insights to Activity of Anthrax Anti-Toxin, Valortim The International Journal of Cancer Publishes Studies on Generex Biotechnology's Anti-cancer Activity of Its Immunotherapeutic Vaccine OncoGenex and Isis Report Encouraging Interim Phase II Data in Advanced Prostate Cancer, Affirm Phase III Clinical Trial Plans Almac Clinical Technologies Launches IXR Express: A new way for clients to accelerate the clinical trial process

Clinical Trial Results Archive

2005

April

More News Resources

(web6)